Literature DB >> 19191635

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Peter G Pappas1, Carol A Kauffman, David Andes, Daniel K Benjamin, Thierry F Calandra, John E Edwards, Scott G Filler, John F Fisher, Bart-Jan Kullberg, Luis Ostrosky-Zeichner, Annette C Reboli, John H Rex, Thomas J Walsh, Jack D Sobel.   

Abstract

Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191635      PMCID: PMC7294538          DOI: 10.1086/596757

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  292 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

3.  Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin.

Authors:  J P Y Sim; B C S Kho; H S Y Liu; R Yung; J C W Chan
Journal:  Hong Kong Med J       Date:  2005-04       Impact factor: 2.227

4.  Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.

Authors:  P Hegener; P F Troke; G Fätkenheuer; V Diehl; M Ruhnke
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177

5.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

6.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

7.  Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

Authors:  P Eggimann; P Francioli; J Bille; R Schneider; M M Wu; G Chapuis; R Chiolero; A Pannatier; J Schilling; S Geroulanos; M P Glauser; T Calandra
Journal:  Crit Care Med       Date:  1999-06       Impact factor: 7.598

8.  Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine.

Authors:  B Marr; S Gross; C Cunningham; L Weiner
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

Review 9.  Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants.

Authors:  A Penk; L Pittrow
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

10.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

View more
  838 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

2.  The A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia.

Authors:  Jingwen Tan; Jinqing Zhang; Wei Chen; Yi Sun; Zhe Wan; Ruoyu Li; Wei Liu
Journal:  Mycopathologia       Date:  2014-11-15       Impact factor: 2.574

3.  Outcomes following candiduria in extremely low birth weight infants.

Authors:  James L Wynn; Sylvia Tan; Marie G Gantz; Abhik Das; Ronald N Goldberg; Ira Adams-Chapman; Barbara J Stoll; Seetha Shankaran; Michele C Walsh; Kathy J Auten; Nancy A Miller; Pablo J Sánchez; Rosemary D Higgins; C Michael Cotten; P Brian Smith; Daniel K Benjamin
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

4.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

5.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 6.  Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting.

Authors:  Brian D W Chow; Jennifer R Linden; Joseph M Bliss
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

7.  In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Authors:  He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

8.  Early fungal infection in an aortic prosthesis with probable cerebral metastasis: the success of a conservative strategy.

Authors:  Anabela Malho Guedes; Teresa Anastácio de Macedo; Carla Rocha; José Neves; Joana Mapril
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

9.  Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.

Authors:  Mingjuan Liu; Yan Li; Xiaoli Zhao; Yongqing Zhang; Bing Zhai; Qingyi Zhang; Lijun Wang; Yu Zhao; Honghua Li; Quanshun Wang; Chunji Gao; Wenrong Huang; Li Yu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

10.  Candidemia by Candida parapsilosis in a neonatal intensive care unit: human and environmental reservoirs, virulence factors, and antifungal susceptibility.

Authors:  Ralciane de Paula Menezes; Sávia Gonçalves de Oliveira Melo; Meliza Arantes Souza Bessa; Felipe Flávio Silva; Priscila Guerino Vilela Alves; Lúcio Borges Araújo; Mário Paulo Amante Penatti; Vânia Olivetti Steffen Abdallah; Denise von Dollinger de Brito Röder; Reginaldo Dos Santos Pedroso
Journal:  Braz J Microbiol       Date:  2020-02-15       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.